Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807

Selective Interaction of Lansoprazole and Astemizole with Tau Polymers: Potential New Clinical Use in Diagnosis of Alzheimer's Disease

(2017) Leonel E. Rojo et al.   JOURNAL OF ALZHEIMERS DISEASE

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

(2015) Marta Marquié et al.   ANNALS OF NEUROLOGY

Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future

(2015) Manuela Ariza et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tau imaging: early progress and future directions

(2015) Victor L Villemagne et al.   LANCET NEUROLOGY

High Affinity Radiopharmaceuticals Based Upon Lansoprazole for PET Imaging of Aggregated Tau in Alzheimer’s Disease and Progressive Supranuclear Palsy: Synthesis, Preclinical Evaluation, and Lead Selection

(2014) Maria V. Fawaz et al.   ACS Chemical Neuroscience

Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers

(2014) M. Shah et al.   JOURNAL OF NUCLEAR MEDICINE

In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals

(2014) Eduardo Zimmer et al.   Translational Neurodegeneration

[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

(2013) Chun-Fang Xia et al.   Alzheimers & Dementia

Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease

(2013) N. Okamura et al.   JOURNAL OF NUCLEAR MEDICINE

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

(2013) Masahiro Maruyama et al.   NEURON

Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of τ-pathology

(2013) Patrick J. Riss et al.   MedChemComm

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Brain Amyloid Imaging — FDA Approval of Florbetapir F18 Injection

(2012) Lucie Yang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ligand polarizability contributes to tau fibril binding affinity

(2011) Jordan R. Jensen et al.   BIOORGANIC & MEDICINAL CHEMISTRY

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease

(2011) M. T. Fodero-Tavoletti et al.   BRAIN

Silver-catalyzed cascade reaction of o-aminoaryl compounds with alkynes: an aniline mediated synthesis of 2-substituted quinolines

(2011) Hongfeng Li et al.   TETRAHEDRON LETTERS

Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents

(2010) Franco Chimenti et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Development of Tau Aggregation Inhibitors for Alzheimer's Disease

(2009) Bruno Bulic et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

PET radiotracers: crossing the blood–brain barrier and surviving metabolism

(2009) Victor W. Pike   TRENDS IN PHARMACOLOGICAL SCIENCES

Synthesis of 18F-labelled 2-(4′-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB

(2008) K. Serdons et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS